肿瘤细胞治疗研究
ALL SOURCES
mRNA-LNP vaccine providing antigen and co-stimulation in the tumor microenvironment enhances CAR T cell function (CART-Vac).
这些发现提示，CART-Vac 可调节肿瘤微环境，为提升 CAR-T 细胞在实体瘤中的治疗疗效提供了一种有前景的策略。
Integrated Transcriptomics of Human and Canine Osteosarcoma Reveals Species Stemness and Trabectedin Sensitivity.
我们的研究为人类和犬类OS提供了一个全面的比较分子框架。
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinica
采用TBI-1301过继性免疫疗法选择性靶向NY-ESO-1阳性肿瘤细胞，似乎是治疗晚期或复发性SS的一种有前景的策略，且毒性可接受。
Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma.
本研究证明了在临床环境中靶向FSTL1-ALCAM轴治疗OS的合理性。
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Kirsten大鼠肉瘤病毒癌基因同源物（KRAS）是20世纪80年代初在人类癌症中最早被鉴定的驱动癌基因之一。
The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
约 30% 的骨肉瘤患者存在 HER2 过表达，针对骨肉瘤的 HER2 靶向治疗以及 HER2 的预后和/或预测价值也已被研究。
Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours.
B10 CAR-T细胞在体外和体内对RCC和骨肉瘤细胞显示出特异性细胞毒性。靶向CSC/CIC抗原DNAJB8的B10 CAR-T细胞可能是癌和肉瘤的候选免疫疗法。
Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocel
所有接受该免疫治疗的患者均完成了至少 2 年的随访，且无 HCC 复发证据（中位随访 96 个月 [范围 17-121 个月]）。
The prognostic value of systemic inflammatory response index (SIRI) and CD8 + tumor-infiltrating lymphocytes for patients with localized undifferentia
在局限性UPS患者中，CD8 + TILs浸润至肿瘤组织可改善高SIRI患者的预后。
Pathological complete response to pembrolizumab in recurrent retroperitoneal dedifferentiated liposarcoma with high tumor mutational burden: a case re
这是首例报道的高TMB复发性腹膜后DDLPS经pembrolizumab治疗达到pCR的病例。肿瘤微环境中高TMB和高TAM密度可能是DDLPS对ICIs应答的预测生物标志物。
MEMBER ACCOUNT
登录成功会直接打开下一页。
